$3.37—Stale · unknown old
NASDAQ • Last print unknown ago
$3.37—Stale · unknown old
Acasti Pharma Inc. is a biotechnology company focused on developing and commercializing innovative prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate, CaPre, is a prescription omega-3 fatty acid medication aimed at lowering triglyceride levels in patients with severe hypertriglyceridemia, primarily targeting the U.S. market.
Acasti Pharma generates revenue through the sale of its prescription drug products, particularly CaPre, which is positioned to compete in the growing market for triglyceride-lowering therapies. The company's competitive advantage lies in its proprietary formulation and clinical data supporting the efficacy of CaPre, which may allow for premium pricing.
Clinical trial results for CaPre, particularly Phase 3 outcomes
Regulatory approvals from the FDA for CaPre
Partnership or licensing agreements with larger pharmaceutical companies
Market adoption rates of CaPre post-launch
Regulatory changes impacting drug approval processes
Technological advancements in alternative therapies
Emergence of generic competitors post-patent expiration
Established pharmaceutical companies entering the triglyceride-lowering market
Negative cash flow impacting operational sustainability
Dependence on external financing for R&D activities
low - Acasti operates in a niche market with specialized products that are less sensitive to economic cycles compared to broader healthcare spending.
Minimal impact as Acasti has no debt; however, higher rates could affect the cost of capital for future financing.
minimal
growth - investors looking for high-risk, high-reward opportunities in biotechnology.
high - the stock has shown significant volatility, particularly around clinical trial announcements.